Not Signed In - US FDA Grants Immtech's Oral Drug Candidate Pafuramidine (DB289) Orphan Drug Status For Treatment Of PCP
Wed, 22 Nov 2006 08:00 AM EST
... Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Pafuramidine (DB289) to treat Pneumocystis jiroveci pneumonia (PCP). PCP is a common life-threatening opportunistic infection in HIV/AIDS and other immunosuppressed patients. [click link for full article] ...
Related Topics
- Drug Abuse
- Drug Safety
- Prescription Drugs
- Prescription Drug Abuse
- Prescription Drugs Abuse
- Drug Information
- Drug Side Effects
- Treatment
- Treatments
- Memantine
- Club Drugs
- Impotence
- Narcolepsy
- Oral Health
- Tysabri
- Abuse
- Rosiglitazone and Metformin
- Thalidomide
- Pregnancy and Substance Abuse
- Cutaneous Drug Reactions
email this page
print this page
bookmark this page
feedback on this page
